How is it possible to spend tens of billions of dollars developing drugs to treat a serious disease that affects millions of people, and yet end up with something that does not work? This is a mystery that has bedevilled Alzheimer’s research for years.
A new review of the evidence has concluded that the leading class of Alzheimer’s drugs “probably result in little to no difference” in a range of measures, including reducing dementia severity. This finding was quickly used to further justify the NHS’s decision two years ago not to fund these drugs.
